News | December 26, 2023
AstraZeneca to acquire China's Gracell Biotechnologies for US $1.2 billion
Furthering cell therapy ambition across oncology and autoimmune diseases
Furthering cell therapy ambition across oncology and autoimmune diseases
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
AAT is a substantial socio-economic burden to livestock farmers in Sub-Saharan Africa, affecting and killing millions of cattle every year
Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Need to harmonize traditional and modern medicine to combat alarming health problems
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
